CLINICAL TRIALS PROFILE FOR AFICAMTEN
✉ Email this page to a colleague
Clinical Trials for Aficamten
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT05186818 ↗ | CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM | Not yet recruiting | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Phase 3 | The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction |
| NCT05186818 ↗ | CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM | Not yet recruiting | Cytokinetics | Phase 3 | The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction |
| NCT05767346 ↗ | The Purpose of This Study is to Compare the Efficacy and Safety of Aficamten (CK-3773274) Compared With Metoprolol Succinate in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction | Not yet recruiting | Cytokinetics | Phase 3 | The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction |
| NCT05924815 ↗ | Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval | Completed | Cytokinetics | Phase 1 | This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A (Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT Study) is a randomized, double-blind (with respect to aficamten and matching placebo), positive- and placebo-controlled, single-dose, 3-way crossover study to evaluate the effect of aficamten administration on QT/QTc interval. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Aficamten
Condition Name
| Condition Name | |
| Intervention | Trials |
| Obstructive Hypertrophic Cardiomyopathy (oHCM) | 2 |
| Healthy Participants | 1 |
| Obstructive Hypertrophic Cardiomyopathy | 1 |
| Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Aficamten
Trials by Country
Clinical Trial Progress for Aficamten
Clinical Trial Phase
Clinical Trial Sponsors for Aficamten
Sponsor Name
